A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma
Phase of Trial: Phase II/III
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Glycopyrrolate (Primary) ; Olodaterol/tiotropium bromide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 22 Mar 2018 Status changed from active, no longer recruiting to recruiting.
- 19 Mar 2018 Planned End Date changed from 15 Feb 2019 to 24 May 2019.
- 19 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.